| 
 
 Session Speaker
 The New Approach to Affect the Bioavailibility of Solid Drugs
 Valeriy Komarov
 Russia
 
 The bioavailability and farmacokinetics of solid-state particles for 
            drug applications prepared from metastable solid-phases is discussed 
            in the context of drug delivery systems. Metastable solid-phases are 
            prepared by drug or joint drug and exipients vapor deposition on solid 
            surface. Stability at storage of final powders was more than 1-2 years.
 Since most drugs are solids, drug design must consider solid state 
            properties such as supramolecular structure, the degree and type of 
            dispersivity, and drug and excipient combination efficiency. Modification 
            of these properties may influence the physico-chemical properties 
            and, as a consequence, bioavailability of the drug.
 Main advantages of this approach rather to the most common approaches 
            for drug modification, first off all, high universality of technology 
            and ability to solve the problems inaccessible to other approaches, 
            are discussed. For poorly soluble drugs micronization without exipients 
            at certain conditions increased Cmax and decreased Tmax in 2-3 times 
            and at joint micronization usual exipients got ability to considerably 
            change the bioavailability of drugs. The bioavailability of water 
            soluble drugs could be increased in several times or at other conditions 
            of micronization rate and level of drug absorbsion could be strongly 
            reduced, that is necessary for creation of medicinal forms of the 
            prolonged action.
 
 Examples involving different drugs are presented, which led to the 
            formation new polymorphs, new size distribution, new kind of joint 
            solid state with exipients that sharply change physico-chemical behaviour 
            and farmacokinetic properties and could be used to create new drug 
            formulations with enhanced bioavailability or prolonged action.
 
 References:
 1. Sergeev, G. B., Komarov, V. S., Mol. Cryst. Liq. Cryst., Vol. 456, 
            pp. 107-115, 2006.
 2. Komarov,V. S. (2008). WO 2008/010741 A1.
 3. Komarov,V. S. (2008). WO 2008/030134 A1.
 4. Komarov, V. S., Morozov, Y.N, Zuev, A.P. (2008). Patent RU23 31409.
 5. Komarov, V. S. (2009). Patent RU2347565.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 |